Courtney Blair, MD
Allergy & Immunology · Mc Lean, VANPI 1730121344
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,126 of the $138,613 with a category attached, or 66.5%. 38 manufacturers reported payments, led by GSK at 35.8% of the total. 2025 is the largest year on record at $38,804, 2.9 times the $13,611 reported in 2019. Among allergy & immunology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 671 payments — averaging $206.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$50K
- Genentech USA, Inc.$44K
- CSL Behring$12K
- Pfizer$8K
- Biocryst Pharmaceuticals, Inc.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- plus $12K from 32 others
What the payments were for
- Consulting fees$25,04118%
- Speaking & faculty fees$92,12666%
- Travel & lodging$7,0155%
- Food & beverage$14,23110%
- Education$2010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 91 | $49,692 |
| Genentech USA, Inc. | 63 | $44,265 |
| CSL Behring | 42 | $11,985 |
| Pfizer | 72 | $8,419 |
| Biocryst Pharmaceuticals, Inc. | 22 | $7,128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $4,702 |
| Sanofi | 47 | $3,197 |
| Teva Pharmaceuticals USA, Inc. | 10 | $1,807 |
| AstraZeneca | 84 | $1,794 |
| Biocryst US Sales Co., LLC | 15 | $1,230 |
| Optinose US, Inc. | 38 | $682 |
| Alk-abello, Inc | 10 | $548 |
| Regeneron Healthcare Solutions, Inc. | 19 | $494 |
| Aimmune Therapeutics, Inc. | 5 | $420 |
| Pharming Healthcare, Inc. | 16 | $381 |
| Incyte Corporation | 12 | $289 |
| Kaleo, Inc. | 12 | $237 |
| Amgen(2 entities) | 11 | $209 |
| AbbVie | 7 | $152 |
| Novartis | 7 | $137 |
| Shire North American Group Inc | 7 | $133 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $96 |
| Grifols USA, LLC | 4 | $78 |
| Boehringer Ingelheim | 3 | $64 |
| Octapharma USA, Inc. | 4 | $63 |
| Sanofi US Services Inc. | 1 | $55 |
| Hikma Pharmaceuticals USA | 3 | $50 |
| Lilly USA, LLC | 2 | $48 |
| Organon | 2 | $48 |
| Eyevance Pharmaceuticals LLC | 3 | $43 |
| USWM, LLC | 2 | $42 |
| Ionis Pharmaceuticals, Inc. | 1 | $22 |
| Bio Products Laboratory USA, Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $21 |
| LEO Pharma Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Jubilant Hollisterstier LLC | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$138,613 in reported general payments places this provider in the 95th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $105,658 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $89,934 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $87,664 |
| NucalaMepolizumab | 23 | $85,495 |
| Dupixent SyringeDupilumab | 15 | $64,114 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $20,963 |
| Epinephrine | 59 | $11,562 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,219 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 44 | $9,194 |
| Atrovent HfaIpratropium Bromide | 11 | $8,155 |
| Arnuity ElliptaFluticasone Furoate | 11 | $6,247 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $4,708 |
| Ipratropium Bromide | 79 | $3,173 |
| Montelukast Sodium | 158 | $2,290 |
| Azelastine Hcl | 43 | $2,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Arnuity Ellipta | $49,692 | $179,40790 claims |
| CSL BehringHizentra | $11,985 | $105,65812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $4,702 | $89,93413 claims |
| AstraZenecaBreztri Aerosphere | $1,794 | $20,96312 claims |
| Hikma Pharmaceuticals USAEpinephrine | $50 | $11,56259 claims |
| Boehringer IngelheimSpiriva Respimat | $64 | $9,21912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 allergy & immunology providers in Virginia.
Other allergy & immunology in Mc Lean
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Andrew KimFredericksburg$104K
- Behnam DaghighLeesburg$99K
- Ananth ThyagarajanBurke$97K
- Larry BorishCharlottesville$92K
- Oral AlpanSpringfield$88K
- Angela HoganNorfolk$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.